Literature DB >> 21515306

Cross protection against lethal West Nile virus challenge in mice immunized with recombinant E protein domain III of Japanese encephalitis virus.

Shi-Hua Li1, Xiao-Feng Li, Hui Zhao, Tao Jiang, Yong-Qiang Deng, Xue-Dong Yu, Qing-Yu Zhu, E-De Qin, Cheng-Feng Qin.   

Abstract

Japanese encephalitis virus (JEV) and West Nile virus (WNV) are closely related mosquito-borne flaviviruses that cause severe encephalitic diseases with global impact. Cross protection among JEV and WNV has been previously described, and most cross reactive epitopes were identified within the domain II of E protein (EDII). In this study, the E protein domain III (EDIII) of JEV was successfully expressed in Escherichia coli, purified by a Ni-NTA column and characterized by Western blotting assay. Competitive inhibition assay showed that this recombinant JEV EDIII blocks the entry of JEV into BHK-21 cells. Mice immunized with the recombinant JEV EDIII developed high IgG and neutralizing antibodies titers against JEV. Most importantly, antibodies induced by JEV EDIII could neutralize WNV in vitro and partially protected mice against lethal WNV challenge. These results demonstrate that immunization with JEV EDIII induces cross-protective immunity against WNV infection, indicating a possible role of EDIII for the cross-protection among flavivirus.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515306     DOI: 10.1016/j.imlet.2011.04.003

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

2.  Inhibition of Japanese encephalitis virus infection by flavivirus recombinant E protein domain III.

Authors:  Jingjing Fan; Yi Liu; Xuping Xie; Bo Zhang; Zhiming Yuan
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

3.  Flavivirus-induced antibody cross-reactivity.

Authors:  Karen L Mansfield; Daniel L Horton; Nicholas Johnson; Li Li; Alan D T Barrett; Derek J Smith; Sareen E Galbraith; Tom Solomon; Anthony R Fooks
Journal:  J Gen Virol       Date:  2011-09-07       Impact factor: 3.891

4.  Seeking Flavivirus Cross-Protective Immunity.

Authors:  Lorrany Dos Santos Franco; Letícia Tsieme Gushi; Wilson Barros Luiz; Jaime Henrique Amorim
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

5.  JEV Infection Induces M-MDSC Differentiation Into CD3+ Macrophages in the Brain.

Authors:  Nan Zhang; Xiaochen Gao; Weijia Zhang; Junyao Xiong; Xiaojian Cao; Zhen F Fu; Min Cui
Journal:  Front Immunol       Date:  2022-04-21       Impact factor: 8.786

Review 6.  Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases.

Authors:  Baohua Hou; Hui Chen; Na Gao; Jing An
Journal:  Viruses       Date:  2022-06-02       Impact factor: 5.818

7.  Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.

Authors:  Hui Zhao; Tao Jiang; Xi-Zhen Zhou; Yong-Qiang Deng; Xiao-Feng Li; Shui-Ping Chen; Shun-Ya Zhu; Xi Zhou; E-De Qin; Cheng-Feng Qin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

8.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.